OBM Neurobiology is an international peer-reviewed Open Access journal published quarterly online by LIDSEN Publishing Inc. By design, the scope of OBM Neurobiology is broad, so as to reflect the multidisciplinary nature of the field of Neurobiology that interfaces biology with the fundamental and clinical neurosciences. As such, OBM Neurobiology embraces rigorous multidisciplinary investigations into the form and function of neurons and glia that make up the nervous system, either individually or in ensemble, in health or disease. OBM Neurobiology welcomes original contributions that employ a combination of molecular, cellular, systems and behavioral approaches to report novel neuroanatomical, neuropharmacological, neurophysiological and neurobehavioral findings related to the following aspects of the nervous system: Signal Transduction and Neurotransmission; Neural Circuits and Systems Neurobiology; Nervous System Development and Aging; Neurobiology of Nervous System Diseases (e.g., Developmental Brain Disorders; Neurodegenerative Disorders).

OBM Neurobiology publishes research articles, technical reports and invited topical reviews. Although the OBM Neurobiology Editorial Board encourages authors to be succinct, there is no restriction on the length of the papers. Authors should present their results in as much detail as possible, as reviewers are encouraged to emphasize scientific rigor and reproducibility.

Archiving: full-text archived in CLOCKSS.

Rapid publication: manuscripts are undertaken in 11.8 days from acceptance to publication (median values for papers published in this journal in the second half of 2021, 1-2 days of FREE language polishing time is also included in this period).

Current Issue: 2022  Archive: 2021 2020 2019 2018 2017
Open Access Original Research

One Week of Continuous Anesthesia by Propofol (2,6-Diisopropylphenol) Does Not Cause Neurobehavioral Changes after Recovery in the Mexican Axolotl Salamander

Sofie Amalie Andersson 1, Mathias Møller Thygesen 1,2, Anita Dittrich 1, Henrik Lauridsen 1,*

  1. Department of Clinical Medicine, Aarhus University, Aarhus N, Denmark

  2. Department of Neurosurgery, Aarhus University Hospital, Denmark

Correspondence: Henrik Lauridsen

Academic Editor: Thomas H.J. Burne

Special Issue: Neurotoxicity of Anesthetics

Received: March 07, 2022 | Accepted: June 29, 2022 | Published: July 06, 2022

OBM Neurobiology 2022, Volume 6, Issue 3, doi:10.21926/obm.neurobiol.2203127

Recommended citation: Andersson SA, Thygesen MM, Dittrich A, Lauridsen H. One Week of Continuous Anesthesia by Propofol (2,6-Diisopropylphenol) Does Not Cause Neurobehavioral Changes after Recovery in the Mexican Axolotl Salamander. OBM Neurobiology 2022; 6(3): 127; doi:10.21926/obm.neurobiol.2203127.

© 2022 by the authors. This is an open access article distributed under the conditions of the Creative Commons by Attribution License, which permits unrestricted use, distribution, and reproduction in any medium or format, provided the original work is correctly cited.

Abstract

The Mexican axolotl salamander is an important model species in regenerative medical research and experiments involving this species often require anesthesia which is usually limited to the duration of the surgical procedure or other interventions, usually lasting no more than a few hours. This study aimed to examine the potential for increasing the duration of anesthesia by continued propofol infusion for a week. Neurobehavioral changes in response to prolonged anesthesia were evaluated after two and seven days of recovery by assessing the resultant changes in response to tactile and nociceptive stimulation and tracking activity levels post-anesthesia. No indications of neurotoxicity were found, but significant and reversible swelling was observed. This concern should be addressed before attempting to extend the duration of anesthesia beyond one week in future experiments. In summary, our study demonstrated the potential for long-term anesthesia in the Mexican axolotl with no indications of neurotoxicity.

Graphical abstract

Click to view original image

Keywords

Ambystoma mexicanum; long-term anesthesia; recovery

1. Introduction

The Mexican axolotl Ambystoma mexicanum (Shaw and Nodder, 1798) is a salamander species having high regenerative abilities and has been widely used as a laboratory model to explore limb regeneration, spinal cord injury, and cardiac regeneration [1,2,3]. In order to reduce the variance associated with animal behavior during regeneration, we ultimately seek to establish a long-term anesthesia model for the axolotl, spanning the entire regenerative period. Previous studies have shown that propofol (2,6-diisopropylphenol) can anesthetize axolotls and provide stable anesthesia. [4]. Propofol is preferred as a long-term anesthetic agent in comparison to other commonly used anesthetics in fishes and amphibians, MS-222 (ethyl 3-aminobenzoate methanesulfonic acid) and benzocaine (ethyl 4-aminobenzoate), that require organic solvents to dissolve in water and buffers to alleviate pH changes, which may cause skin irritation or lesions that could reduce animal welfare during prolonged exposure [5]. Additionally, propofol is a hypnotic and non-depolarizing agent [4,6] and does not affect cardiac function or regenerative capacity if provided in repeated doses [4]. However, anesthetic agents may be neurotoxic to the developing brain and cause long-term neurocognitive impairments in rodents [7] in a duration-dependent manner [8]. Therefore, our study aimed to evaluate the potential neurotoxicity of one week of continuous anesthesia by propofol in the axolotl, assessed by neurobehavioral changes to tactile and nociceptive stimuli and changes in the activity level.

2. Materials and Methods

2.1 Ethics Statement

The study was carried out in accordance with the Danish legislation for the care and use of laboratory animals. The experiments and housing conditions were approved by the Danish National Animal Experiments Inspectorate (protocol# 2015–15–0201–00615).

2.2 Animals

Animals used in this study were large Mexican axolotls (n = 6, mean body mass ± STD 63.2 g ± 17.4 g) of approximately 2 years of age. Of these animals, two and four were females and males, respectively. Animals were housed individually in plastic containers (78 × 56 × 18 cm3) containing 21 L of water with weekly water changes and a 12 h:12 h light/dark cycle. Furthermore, all anesthetized animals were housed together in a single container (78 × 56 × 18 cm3) with 10 L of aerated water to reduce the amount of propofol-contaminated wastewater. Animals were kept on fasting for two weeks before anesthesia and for the entire study duration.

2.3 Anesthesia

Propofol (10 g*L–1 concentration, Propofol B, Braun, Melsungen, Germany) was used as the anesthetic agent throughout the study. Anesthesia was induced by immersing axolotls in an induction bath containing propofol (10.5 mg*L–1) for 30–40 min before moving them to a propofol maintenance concentration (3.5 mg*L–1). Undiluted propofol was continuously infused into the water by an infusion pump to replace the metabolized propofol. During the first 24 h of anesthesia, propofol was infused at a rate of 1.75 mL*day–1. Additionally, anesthesia depth was evaluated by turning axolotls on their backs; the anesthesia depth was deemed appropriate in the absence of a righting reflex and lack of response to tactile stimuli. At signs of inadequate anesthesia, the infusion rate was increased to 3.5 mL*day–1. Two periods of propofol anesthesia were evaluated: 24 h and seven days. Before the induction of the first anesthetic period, animals were kept fasting for two weeks to avoid gastrointestinal complications during the anesthesia.

2.4 Neurobehavioral Assessment

Animals were neurologically examined after two and seven days of recovery following each period of anesthesia. Animals were stimulated with both tactile (gentle tap against the side of the head) and nociceptive (pinching of the tail) stimuli [2]. For both, stimulation was conducted in triplicate, with the maximum score defining the overall test score. The responses to stimulation were scored as follows: 1: No reaction to stimulation. 2: Local movement. 3: Immediate, coordinated flight response.

Activity level was measured over 2 h at the same time of the day (9–11 am) after 18 h with no disturbance using 2 frame*s–1 time-lapse recording (GoPro Hero 4 edition). From these recordings, the total activity time, the total distance traveled, and the efficient speed levels were extracted. Efficient speed describes the average speed of the animal traveling from one location to another in the aquarium. This parameter was added as an additional measure of coordinated movements since axolotls generally tend to “paddle” against a corner, thus, not covering any distance while still being active. Individual frames were extracted and analyzed using the ImageJ 1.50e tool by placing points of interest at the head of each animal before and after every movement.

2.5 Statistical analysis

For continuous data, repeated measures ANOVA test was used for omnibus testing of statistically significant differences between the time points. Dunnett’s test was used to identify the time points with significant differences from the baseline levels. Friedman’s test was used for analyzing the ordinal data pertaining to neurological examination. We considered p-values <0.05 to signify statistical significance. Shaded areas in the figures indicated 95% confidence intervals. All statistical analyses were carried out in STATA 16 (Stata Statistical Software: Release 16. College Station, TX: StataCorp LLC.)

3. Results

3.1 Neurobehavioral Assessment after Long-Term Anesthesia

Repeated measures ANOVA detected no significant effect of anesthesia on total activity time (F (4, 20) = 1.09, p = 0.387) and on total distance traveled (F (4, 20) = 1.12, p = 0.373).

Repeated measures ANOVA detected significant effect of anesthesia on efficient speed (F (4, 20) = 4.02, p = 0.0150). Dunnett’s test did not detect a significant difference in efficient speed from baseline at any time point, however, efficient speed decreased on both 2-day recovery time points (two days recovery after 24 h anesthesia vs. baseline: delta = –0.351, 95% CI = [-0.795, 0.0931] p = 0.151; two days recovery after 7 d anesthesia vs. baseline: delta = –0.399, 95% CI = [-0.843, 0.0457] p = 0.088).

Tactile examination two and seven days after the anesthesia period yielded a non-significant difference when compared to the baseline (p = 0.09). Nociceptive examination detected no significant difference at any time point, with all animals achieving the highest score throughout the entire study.

3.2 Effects of Long-Term Anesthesia on Body Mass

Repeated measures ANOVA detected a significant effect on body mass (F (9, 45) = 16.65, p< 0.001) while Dunnett’s test revealed that body mass was significantly increased due to swelling at 13 (delta = 0.203, 95% CI = [0.0831, 0.324] p< 0.000), 15 (delta = 0.155, 95% CI = [0.0350, 0.276] p = 0.006), and 17 (delta = 0.131, 95% CI = [0.0111, 0.252] p = 0.026) days, after initiating the experiment. The body mass increase during anesthesia was reversed during the recovery period, resulting in a significant decrease of body mass relative to baseline at seven days of recovery following a week of anesthesia i.e., after 22 days of fasting (delta = –0.150, 95% CI = [-0.270, 0.0298] p = 0.008, Figure 1).

Click to view original image

Figure 1 Effects of long-term anesthesia on activity levels and body mass. Total activity (top left), total distance (top right), and efficient speed (bottom left) were extracted from 2 h time-lapse recordings of -activity levels. Top left + right: No significant change in total activity time or distance traveled was detected during activity tracking when compared with activity levels before anesthesia. Bottom left: effective speed decreased on day 2 of recovery after anesthesia. Bottom right: Change in body mass during and after anesthesia. Body mass significantly increased during anesthesia but rapidly returned to normal during the recovery. Grey areas indicate anesthesia while dotted lines denote day 7 of recovery. Shaded areas indicate 95% confidence intervals. 1D-AN 2DR = day 2 of recovery after 24 h anesthesia; 1D-AN 7DR = day 7 of recovery after 24 h anesthesia; 7D-AN 2DR = day 2 of recovery after one week of anesthesia and 7D-AN 7DR = day 7 of recovery after one week of anesthesia.

4. Discussion

In this study, we demonstrated the efficacy of propofol in providing one week of continuous stable anesthesia to axolotls. This is an anesthesia duration nearly twice as long as previously reported for other species [9].

Axolotls showed no changes in the total activity time, or the distance traveled during activity tracking used in this study as an indicator of retained neurological function. The non-significant change in response to tactile and nociceptive stimuli is a gross indicator of preserved sensory function. Combined with the inconsequential changes in the activity level (active time and distance traveled), propofol is seemingly safe to use in axolotls for a week of anesthesia without any irreversible adverse effects. The reduction in efficient speed after both 2-day recovery time points (two days of recovery after 24 h and seven days of anesthesia) was reversed after a week of recovery, and the activity level was back to normal.

During anesthesia, a significant increase in body mass was observed, which may be related to impaired lymphatic function of maintaining body fluid levels in the hypoosmotic environment. Although this body mass increase was reversible, as indicated by the return to baseline levels within a few days of recovery, the relevance of using isosmotic aquarium solutions before initiating longer periods of anesthesia needs to be addressed. The increase in water absorption capacity might hamper the circulatory system’s function to a degree incompatible with long-term survival in anesthesia. The observed reduction in body mass was predictable due to the fasting state of animals for the entire study duration to avoid gastrointestinal complications.

From an ethical perspective, the implementation of anesthetized animal models in regenerative research might reduce the suffering associated with the regenerative process. A potential complication for an extended anesthetic period is propofol infusion syndrome, a rare and lethal complication reported in humans with prolonged propofol administration (>48 h). This syndrome is characterized by metabolic acidosis, rhabdomyolysis, bradycardia, and liver failure [10]. From a practical perspective, using fully anesthetized animals could reduce the variability levels due to individual behavior and thereby increase the quality of research as well as reduce the number of animals needed to perform a study with sufficient power. Long-term, stable anesthesia also allows the initiation of new potential experimental studies spanning several days. An extended anesthetic period could also be used for imaging live-cell migration and scar modulation in regenerating tissues, following the activity of immune cells during regeneration, or tracing the metabolism of radiolabeled metabolites in regenerative animals uncoupled from normally distributed behavioral traits. Moreover, our study used large axolotls; however, smaller animals might be used for such studies, although this has not been initiated in our study. The axolotls must, however, be large enough to handle the long periods of fasting associated with extended anesthetic duration. Additionally, long-term anesthesia of smaller axolotls may require a modification of the propofol infusion rate to avoid the risk of overdose in the smaller animals.

5. Conclusion

In conclusion, we show that long-term anesthesia of the Mexican axolotl is possible for a week with minor physiological effects (increased body mass and swelling) but without any signs of neurological impairment.

Author Contributions

SAA, MT, AD and HL conceptualized the study. SAA performed all experiments with help from AD and HL. SAA performed neurological examinations and analyzed activity data. MT performed statistical analysis. SAA drafted the manuscript. All authors contributed to and approved the final manuscript.

Funding

HL was funded by the Lundbeck Foundation (R324-2019-1470) and the Velux Foundations (00022458) during the making of this study.

Competing Interests

The authors have declared that no competing interests exist.

References

  1. Roy S, Gatien S. Regeneration in axolotls: A model to aim for! Exp Gerontol. 2008; 43: 968-973. [CrossRef]
  2. Thygesen MM, Lauridsen H, Pedersen M, Orlowski D, Mikkelsen TW, Rasmussen MM. A clinically relevant blunt spinal cord injury model in the regeneration competent axolotl (Ambystoma mexicanum) tail. Exp Ther Med. 2019; 17: 2322-2328. [CrossRef]
  3. Cano-Martínez A, Vargas-González A, Guarner-Lans V, Prado-Zayago E, León-Olea M, Nieto-Lima B. Functional and structural regeneration in the axolotl heart (Ambystoma mexicanum) after partial ventricular amputation. Arch Cardiol Mex. 2010; 80: 79-86.
  4. Thygesen MM, Rasmussen MM, Madsen JG, Pedersen M, Lauridsen H. Propofol (2,6-diisopropylphenol) is an applicable immersion anesthetic in the axolotl with potential uses in hemodynamic and neurophysiological experiments. Regeneration. 2017; 4: 124-131. [CrossRef]
  5. Mitchell MA. Anesthetic considerations for amphibians. J Exot Pet Med. 2009; 18: 40-49. [CrossRef]
  6. Steinbacher DM. Propofol: A sedative-hypnotic anesthetic agent for use in ambulatory procedures. Anesth Prog. 2001; 48: 66-71.
  7. Murphy KL, Baxter MG. Long-term effects of neonatal single or multiple isoflurane exposures on spatial memory in rats. Front Neurol. 2013; 4: 87. [CrossRef]
  8. Disma N, Mondardini MC, Terrando N, Absalom AR, Bilotta F. A systematic review of methodology applied during preclinical anesthetic neurotoxicity studies: Important issues and lessons relevant to the design of future clinical research. Paediatr Anaesth. 2016; 26: 6-36. [CrossRef]
  9. Goldmann C, Ghofrani A, Hafemann B, Fuchs P, Khorram-Seffat R, Afify M, et al. Combination anesthesia with ketamine and pentobarbital: A long-term porcine model. Res Exp Med. 1999; 199: 35-50. [CrossRef]
  10. Fodale V, La Monaca E. Propofol infusion syndrome: An overview of a perplexing disease. Drug Saf. 2008; 31: 293-303. [CrossRef]
Announcement
Newsletter
Download PDF Download Citation
0 0

TOP